Hematological malignancies escape from NK cell innate immune surveillance: Mechanisms and therapeutic implications

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Farnault, Laure ^a,b   Sanchez, Carole ^a   Baier, Céline ^a   Le Treut, Thérse ^c   Costello, Régis T ^a  

^a Aix Marseille university   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c HÔPITAL NORD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BORTEZOMIB; IMATINIB; LENALIDOMIDE; PANOBINOSTAT; RETINOIC ACID; THALIDOMIDE; VORINOSTAT; CYTOKINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; HEMATOLOGIC DISEASE; IMMUNOLOGY; IMMUNOTHERAPY; TUMOR ESCAPE;

CYTOKINES; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; TUMOR ESCAPE;

EID: 84864914363     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/421702     Document Type: Review

References (77)

1. Ruggeri L., Mancusi A., Burchielli E., Aversa F., Martelli M. F., Velardi A., Natural killer cell alloreactivity in allogeneic hematopoietic transplantation Current Opinion in Oncology 2007 19 2 142 147 (Pubitemid 46204354)
2. Maghazachi A. A., Role of chemokines in the biology of natural killer cells Current Topics in Microbiology and Immunology 2010 341 37 58
3. Karre K., Express yourself or die: peptides, MHC molecules, and NK cells Science 1995 267 5200 978 979
4. Costello R. T., Gastaut J. A., Olive D., Tumor escape from immune surveillance Archivum Immunologiae et Therapiae Experimentalis 1999 47 2 83 88
5. Kerndrup G., Meyer K., Ellegaard J., Hokland P., Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome Leukemia Research 1984 8 2 239 247 (Pubitemid 14149201)
6. Biassoni R., Cantoni C., Pende D., Sivori S., Parolini S., Vitale M., Bottino C., Moretta A., Human natural killer cell receptors and co-receptors Immunological Reviews 2001 181 203 214 (Pubitemid 32703408)
7. Costello R. T., Fauriat C., Sivori S., Marcenaro E., Olive D., NK cells: innate immunity against hematological malignancies? Trends in Immunology 2004 25 6 328 333 (Pubitemid 38610357)
8. Costello R. T., Sivori S., Marcenaro E., Lafage-Pochitaloff M., Mozziconacci M. J., Reviron D., Gastaut J. A., Pende D., Olive D., Moretta A., Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia Blood 2002 99 10 3661 3667 (Pubitemid 34534536)
9. Sanchez C. J., Le Treut T., Boehrer A., Knoblauch B., Imbert J., Olive D., Costello R. T., Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity Cancer Immunology, Immunotherapy 2011 60 1 1 13
10. Rey J., Veuillen C., Vey N., Bouabdallah R., Olive D., Natural killer and T cells in haematological malignancies: enhancing the immune effectors Trends in Molecular Medicine 2009 15 6 275 284
11. Yokose N., Ogata K., Ito T., An E., Tamura H., Dan K., Hamaguchi H., Sakamaki H., Onozawa Y., Nomura T., Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes Leukemia Research 1994 18 10 777 782 (Pubitemid 24302105)
12. Wetzler M., Baer M. R., Stewart S. J., Donohue K., Ford L., Stewart C. C., Repasky E. A., Ferrone S., HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse Leukemia 2001 15 1 128 133 (Pubitemid 32124077)
13. Classen C. F., Falk C. S., Friesen C., Fulda S., Herr I., Debatin K. M., Natural killer resistance of a drug-resistant leukemia cell line, mediated by up-regulation of HLA class I expression Haematologica 2003 88 5 509 521 (Pubitemid 36648440)
14. Demanet C., Mulder A., Deneys V., Worsham M. J., Maes P., Claas F. H., Ferrone S., Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 2004 103 8 3122 3130 (Pubitemid 38451690)
15. Maki G., Hayes G. M., Naji A., Tyler T., Carosella E. D., Rouas-Freiss N., Gregory S. A., NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G Leukemia 2008 22 5 998 1006 (Pubitemid 351689882)
16. Challa-Malladi M., Lieu Y. K., Califano O., Holmes A.., Bhagat G., Murty V., Dominguez-Sola D., Pasqualucci L., Dalla-Favera R., Combined genetic inactivation of 2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma Cancer Cell 2011 20 6 728 740
17. Carbone E., Neri P., Mesuraca M., Fulciniti M. T., Otsuki T., Pende D., Groh V., Spies T., Pollio G., Cosman D., Catalano L., Tassone P., Rotoli B., Venuta S., HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells Blood 2005 105 1 251 258 (Pubitemid 40053090)
18. Sivori S., Pende D., Bottino C., Marcenaro E., Pessino A., Biassoni R., Moretta L., Moretta A., NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells European Journal of Immunology 1999 29 5 1656 1666 (Pubitemid 29224471)
19. Fauriat C., Just-Landi S., Mallet F., Arnoulet C., Sainty D., Olive D., Costello R. T., Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCR dull phenotype induction Blood 2007 109 1 323 330 (Pubitemid 46053073)
20. Costello R. T., Fauriat C., Olive D., Natural killer cells and immunity against cancer Discovery Medicine 2004 4 23 333 337
21. Costello R. T., Knoblauch B., Sanchez C., Mercier D., Le Treut T., Sébahoun G., Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia Immunology 2012 135 2 151 157
22. Epling-Burnette P. K., Loughran T. P., Survival signals in leukemic large granular lymphocytes Seminars in Hematology 2003 40 3 213 220 (Pubitemid 36842599)
23. Poggi A., Venturino C., Catellani S., Clavio M., Miglino M., Gobbi M., Steinle A., Ghia P., Stella S., Caligaris-Cappio F., Zocchi M. R., V 1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid Cancer Research 2004 64 24 9172 9179 (Pubitemid 39665533)
24. Jinushi M., Vanneman M., Munshi N. C., Tai Y. T., Prabhala R. H., Ritz J., Neuberg D., Anderson K. C., Carrasco D. R., Dranoff G., MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma Proceedings of the National Academy of Sciences of the United States of America 2008 105 4 1285 1290 (Pubitemid 351397045)
25. Romanski A., Bug G., Becker S., Kampfmann M., Seifried E., Hoelzer D., Ottmann O. G., Tonn T., Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia Experimental Hematology 2005 33 3 344 352 (Pubitemid 40261316)
26. Weiss-Steider B., Soto-Cruz I., Martinez-Campos C. A., Mendoza-Rincon J. F., Expression of MICA, MICB and NKG2D in human leukemic myelomonocytic and cervical cancer cells Journal of Experimental and Clinical Cancer Research 2011 30 1, article 37
27. Sanchez-Correa B., Gayoso I., Bergua J. M., Casado J. G., Morgado S., Solana R., Tarazona R., Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients Immunology and Cell Biology 2011 90 109 115
28. Matsuzaki H., Kagimoto T., Oda T., Kawano F., Takatsuki K., Natural killer activity and antibody-dependent cell-mediated cytotoxicity in multiple myeloma Japanese Journal of Clinical Oncology 1985 15 4 611 617
29. Fauriat C., Mallet F., Olive D., Costello R. T., Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma Leukemia 2006 20 4 732 733
30. Nakajima H., Zhao R., Lund T. C., Ward J., Dolan M., Hirsch B., Miller J. S., The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients Journal of Immunology 2002 168 2 643 650 (Pubitemid 34049564)
31. Verhoef G. E. G., De Schouwer P., Ceuppens J. L., Van Damme J., Goossens W., Boogaerts M. A., Measurement of serum cytokine levels in patients with myelodysplastic syndromes Leukemia 1992 6 12 1268 1272 (Pubitemid 23054024)
32. Gersuk G. M., Carmel R., Pattamakom S., Challita P. M., Rabinowitz A. P., Pattengale P. K., Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia veraI: a potential role for platelet-derived growth factor in defective NK cytotoxicity Natural Immunity 1993 12 3 136 151 (Pubitemid 23207637)
33. Wilson E. B., El-Jawhari J. J., Neilson A. L., Hall G. D., Melcher A. A., Meade J. L., Cook G. P., Human tumour immune evasion via TGF- blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity PLoS ONE 2011 6 9
34. Tajima F., Kawatani T., Endo A., Kawasaki H., Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia Leukemia 1996 10 3 478 482 (Pubitemid 26128788)
35. Rowe M., Khanna R., Jacob C. A., Argnet V., Kelly A., Powis S., Belich M., Croom-Carter D., Lee S., Burrows S. R., Trowsdale J., Moss D. J., Rickinson A. B., Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression European Journal of Immunology 1995 25 5 1374 1384
36. Urlacher A., Falkenrodt A., Tongio M. M., Mayer S., HLA Class I antigens on normal and leukemic cells (quantitative analysis) Tissue Antigens 1987 29 5 237 245 (Pubitemid 17102876)
37. Biassoni R., Cantoni C., Marras D., Giron-Michel J., Falco M., Moretta L., Dimasi N., Human Natural Killer cell receptors: insights into their molecular function and structure Journal of Cellular and Molecular Medicine 2003 7 4 376 387 (Pubitemid 44151688)
38. Sanchez-Correa B., Morgado S., Gayoso I., Bergua J. M., Casado J. G., Arcos M. J., Bengochea M. L., Duran E., Solana R., Tarazona R., Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands Cancer Immunology, Immunotherapy 2011 60 8 1195 1205
39. Groh V., Wu J., Yee C., Spies T., Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation Nature 2002 419 6908 734 738 (Pubitemid 35177960)
40. Boissel N., Rea D., Tieng V., Dulphy N., Brun M., Cayuela J. M., Rousselot P., Tamouza R., Le Bouteiller P., Mahon F. X., Steinle A., Charron D., Dombret H., Toubert A., BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia Journal of Immunology 2006 176 8 5108 5116
41. Pende D., Castriconi R., Romagnani P., Spaggiari G. M., Marcenaro S., Dondero A., Lazzeri E., Lasagni L., Martini S., Rivera P., Capobianco A., Moretta L., Moretta A., Bottino C., Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction Blood 2006 107 5 2030 2036 (Pubitemid 43289387)
42. Sivori S., Parolini S., Falco M., Marcenaro E., Biassoni R., Bottino C., Moretta L., Moretta A., 2B4 functions as a co-receptor in human NK cell activation European Journal of Immunology 2000 30 3 787 793 (Pubitemid 30216250)
43. Carayol G., Giron-Michel J., Azzarone B., Castagna L., Cambier N., Mishal Z., Bourhis J. H., Chouaib S., Caignard A., Altered natural killer cell differentiation in CD34+ progenitors from Chronic Myeloid Leukemia patients Oncogene 2000 19 23 2758 2766 (Pubitemid 30339225)
44. Barrett A. J., Savani B. N., Does chemotherapy modify the immune surveillance of hematological malignancies? Leukemia 2009 23 1 53 58
45. Markasz L., Stuber G., Vanherberghen B., Flaberg E., Olah E., Carbone E., Eksborg S., Klein E., Skribek H., Szekely L., Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells Molecular Cancer Therapeutics 2007 6 2 644 654 (Pubitemid 46332465)
46. Ruggeri L., Mancusi A., Capanni M., Urbani E., Carotti A., Aloisi T., Stern M., Pende D., Perruccio K., Burchielli E., Topini F., Bianchi E., Aversa F., Martelli M. F., Velardi A., Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value Blood 2007 110 1 433 440 (Pubitemid 47026866)
47. Farag S. S., Fehniger T. A., Ruggeri L., Velardi A., Caligiuri M. A., Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect Blood 2002 100 6 1935 1947 (Pubitemid 35001221)
48. Ruggeri L., Aversa F., Martelli M. F., Velardi A., Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self Immunological Reviews 2006 214 1 202 218 (Pubitemid 44707912)
49. Willemze R., Ruggeri A., Purtill D., Rodrigues C. A., Gluckman E., Rocha V., Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation? Best Practice and Research 2010 23 2 283 290
50. Miller J. S., Soignier Y., Panoskaltsis-Mortari A., McNearney S. A., Yun G. H., Fautsch S. K., McKenna D., Le C., Defor T. E., Burns L. J., Orchard P. J., Blazar B. R., Wagner J. E., Slungaard A., Weisdorf D. J., Okazaki I. J., McGlave P. B., Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 2005 105 8 3051 3057
51. Curti A., Ruggeri L., D'Addio A., Bontadini A., Dan E., Motta M. R., Trabanelli S., Giudice V., Urbani E., Martinelli G., Paolini S., Fruet F., Isidori A., Parisi S., Bandini G., Baccarani M., Velardi A., Lemoli R. M., Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients Blood 2011 118 12 3273 3279
52. Rubnitz J. E., Inaba H., Ribeiro R. C., Pounds S., Rooney B., Bell T., Pui C. H., Leung W., NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia Journal of Clinical Oncology 2010 28 6 955 959
53. Shi J., Tricot G., Szmania S., Rosen N., Garg T. K., Malaviarachchi P. A., Moreno A., DuPont B., Hsu K. C., Baxter-Lowe L. A., Cottler-Fox M., Shaughnessy J. D., Barlogie B., Van Rhee F., Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation British Journal of Haematology 2008 143 5 641 653
54. Suck G., Oei V. Y. S., Linn Y. C., Ho S. H., Chu S., Choong A., Niam M., Koh M. B. C., Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies Experimental Hematology 2011 39 9 904 914
55. Lion E., Smits E. L. J. M., Berneman Z. N., Van Tendeloo V. F. I., Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN- secretion by human NK cells Leukemia Research 2009 33 4 539 546
56. hlberg R., MacNamara B., Andersson M., Zheng C., Svensson A., Holm G., Hansson M., Porwit-MacDonald A., Bjrkholm M., Sundblad A., Stimulation of T-cell cytokine production and NK-cell function by IL-2, IFN- and histamine treatment during remission of non-Hodgkin's lymphoma Hematology Journal 2003 4 5 336 341 (Pubitemid 37259351)
57. Lehmann C., Zeis M., Uharek L., Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells British Journal of Haematology 2001 114 3 660 665 (Pubitemid 32953648)
58. Brune M., Castaigne S., Catalano J., Gehlsen K., Ho A. D., Hofmann W. K., Hogge D. E., Nilsson B., Or R., Romero A. I., Rowe J. M., Simonsson B., Spearing R., Stadtmauer E. A., Szer J., Wallhult E., Hellstrand K., Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial Blood 2006 108 1 88 96 (Pubitemid 43996626)
59. Romero A. I., Thorén F. B., Aurelius J., Askarieh G., Brune M., Hellstrand K., Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML Scandinavian Journal of Immunology 2009 70 3 194 205
60. Robertson M. J., Role of chemokines in the biology of natural killer cells Journal of Leukocyte Biology 2002 71 2 173 183
61. Kittang A. O., Hatfield K., Sand K., Reikvam H., Bruserud., The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications Current Topics in Microbiology and Immunology 2010 341 149 172
62. Zhang X., Munegowda M. A., Yuan J., Wei Y., Xiang J., Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses Journal of Leukocyte Biology 2010 88 2 393 403
63. Alici E., IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers Current Opinion in Molecular Therapeutics 2010 12 6 724 733
64. De Romeuf C., Dutertre C. A., Le Garff-Tavernier M., Fournier N., Gaucher C., Glacet A., Jorieux S., Bihoreau N., Behrens C. K., Béliard R., Vieillard V., Cazin B., Bourel D., Prost J. F., Teillaud J. L., Merle-Béral H., Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of Fc RIIIA/CD16 British Journal of Haematology 2008 140 6 635 643 (Pubitemid 351300917)
65. Bowles J. A., Wang S. Y., Link B. K., Allan B., Beuerlein G., Campbell M. A., Marquis D., Ondek B., Wooldridge J. E., Smith B. J., Breitmeyer J. B., Weiner G. J., Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab Blood 2006 108 8 2648 2654
66. Renner C., Stehle I., Lee F. T., Hall C., Catimel B., Nice E. C., Mountain A., Rigopoulos A., Brechbiel M. W., Pfreundschuh M., Scott A. M., Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system Cancer Immunology, Immunotherapy 2001 50 2 102 108 (Pubitemid 32424495)
67. Berg S. L., Cairo M. S., Russell H., Ayello J., Ingle A. M., Lau H., Chen N., Adamson P. C., Blaney S. M., Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group phase I consortium report Journal of Clinical Oncology 2011 29 3 316 323
68. Diermayr S., Himmelreich H., Durovic B., Mathys-Schneeberger A., Siegler U., Langenkamp U., Hofsteenge J., Gratwohl A., Tichelli A., Paluszewska M., Wiktor-Jedrzejczak W., Kalberer C. P., Wodnar-Filipowicz A., NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities Blood 2008 111 3 1428 1436 (Pubitemid 351213430)
69. Ogbomo H., Michaelis M., Kreuter J., Doerr H. W., Cinatl J., Histone deacetylase inhibitors suppress natural killer cell cytolytic activity FEBS Letters 2007 581 7 1317 1322 (Pubitemid 46452605)
70. Tang K. F., He C. X., Zeng G. L., Wu J., Song G. B., Shi Y. S., Zhang W. G., Huang A. L., Steinle A., Ren H., Induction of MHC class I-related chain B (MICB) by 5-aza-2′-deoxycytidine Biochemical and Biophysical Research Communications 2008 370 4 578 583
71. Santourlidis S., Trompeter H. I., Weinhold S., Eisermann B., Meyer K. L., Wernet P., Uhrberg M., Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells Journal of Immunology 2002 169 8 4253 4261 (Pubitemid 35178197)
72. Shi J., Tricot G. J., Garg T. K., Malaviarachchi P. A., Szmania S. M., Kellum R. E., Storrie B., Mulder A., Shaughnessy J. D., Barlogie B., Van Rhee F., Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma Blood 2008 111 3 1309 1317 (Pubitemid 351213417)
73. Soriani A., Zingoni A., Cerboni C., Lannitto M. L., Ricciardi M. R., Gialleonardo V. D., Cippitelli M., Fionda C., Petrucci M. T., Guarini A., Fo R., Santoni A., ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype Blood 2009 113 15 3503 3511
74. Valés-Gmez M., Chisholm S. E., Cassady-Cain R. L., Roda-Navarro P., Reyburn H. T., Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors Cancer Research 2008 68 5 1546 1554 (Pubitemid 351346864)
75. Lundqvist A., Abrams S. I., Schrump D. S., Alvarez G., Suffredini D., Berg M., Childs R., Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity Cancer Research 2006 66 14 7317 7325 (Pubitemid 44197714)
76. Poggi A., Catellani S., Garuti A., Pierri I., Gobbi M., Zocchi M. R., Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate Leukemia 2009 23 4 641 648
77. Pierson B. A., Miller J. S., CD56(+bright) and CD56(+dim) natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis Blood 1996 88 6 2279 2287 (Pubitemid 26307932)